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https://doi.org/1Background: Elevated plasma interleukin-6 (IL-6) concentrations are frequently observed in patients with
acute heart failure (AHF). However, the predictive value of serial IL-6 measurements beyond brain natri-
uretic peptide (BNP) remains poorly characterized.
Methods and Results: This was a retrospective analysis of the PROTECT cohort (2033 patients with
AHF). Plasma IL-6 and BNP levels were determined on days 1, 2, 7 and 14 after admission for AHF in
1591 (78.3%), 1462 (71.9%), 1445 (71.1%) and 1451 (71.4%) patients, respectively. The primary endpoint
was 180-day all-cause mortality. The median day-1 IL-6 concentration was 11.1 pg/mL (IQR: 6.6, 20.9)
and decreased to 10.1 pg/mL (IQR: 5.6-18.5) at day-7. Higher cross-sectional IL-6 concentrations at all
time-points predicted the primary endpoint, independent of a risk model for this cohort and changes in
BNP. Each doubling of IL-6 between day-1 and day-7 predicted the primary endpoint independent of base-
line IL-6 concentrations, the risk model, baseline BNP and changes in BNP [HR (95% CI): 1.18 (1.07-
1.30), p=0.0013]. Collectively, 214 (17%) patients experienced at least a doubling of their IL-6 concentra-
tions between day-1 and day-7.
Conclusions: We demonstrate that the temporal evolution patterns of IL-6 in patients with AHF have
additive prognostic value independent of changes in BNP. (J Cardiac Fail 2021;27:808811)
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Elevated plasma concentrations of interleukin-6 (IL-
6) are frequently observed in patients with acute and
chronic heart failure (AHF/CHF) and are associated
with worse clinical outcomes.1 Previous relatively small
cohort studies (n<75) have demonstrated that serial IL-
6 measurements can predict adverse outcomes in
HF.24 However, the prevalence and predictors of ele-
vated serial IL-6 measurements and their relationship
with prognosis in patients with AHF remain poorly
characterized. Additionally, it is unknown whether the
prognostic value of changes in serial IL-6 is indepen-
dent of brain natriuretic peptide (BNP). Therefore, we
investigated the added prognostic value of serial IL-6
measurements in a large, well-characterized cohort of
patients with AHF.
Serial IL-6 in acute heart failure  Markousis-Mavrogenis et al 809Patients and Methods
The design and results of the PROTECT trial have been
described previously. 5 Briefly, PROTECT was a multi-
center randomized, double-blind, placebo-controlled trial
studying rolofylline for the treatment of AHF regardless
of left ventricular ejection fraction (LVEF), with overall
neutral results. Major inclusion criteria for the study
cohort, consisting of 2033 patients, were dyspnea at rest/
minimal activity, impaired renal function, a BNP level
500 pg/mL or an N-terminal pro-BNP level
2000 pg/mL, intravenous loop-diuretic therapy, and
enrollment within 24 hours after admission. The primary
endpoint of this retrospective analysis was all-cause mor-
tality at 180 days, a secondary endpoint of the original
PROTECT trial. Outcomes were independently adjudi-
cated. Serial plasma IL-6 and BNP levels were deter-
mined using high-sensitivity single molecule counting
technology (Singulex Inc.) on days 1, 2, 7 and 14 after
admission in 1591 (78.3%), 1462 (71.9%), 1445 (71.1%)
and 1451 (71.4%) patients, respectively. Changes in IL-6
between baseline (day 1) and day 7 after admission could
be determined in 1256 patients (61.8%). All biomarkers
were transformed to a log2-scale to denote a doubling of
the original values per 1-unit change.
Cox regression analysis was used to investigate the effect of
baseline IL-6 concentrations on 180-day all-cause mortality
(n=278/1591) and to adjust for confounding using a previously
published prognostic model for this cohort5 and baseline BNP.
Landmark analyses6 at days 2, 7 and 14 were used to investi-
gate time-dependent effects of IL-6 on prognosis using the
cross-sectional IL-6 measurements at the corresponding time-
points. A separate landmark analysis was performed using the
log2-fold change in IL-6 levels between baseline and day 7.
Each landmark analysis was also corrected stepwise for the
same risk model and for changes in BNP concentrations
between the landmark and the immediately preceding time-
point, as well as BNP and IL-6 concentrations of the immedi-
ately preceding timepoint. Statistical analyses were carried out
using R-Studio v.3.6.0.Table 1. Cox regression and landmark analyses for predicting the pri
corresponding endpoint, the measured IL-6 levels were used as predictor
in a stepwise manner. Hazard ratios are presented for each
Model
Day 1 Day 2
HR (95% CI) p-value HR (95% CI) p-value
A. 1.38 (1.29-1.48) <0.0001* 1.32 (1.18-1.47) <0.0001*
B. 1.27 (1.17-1.37) <0.0001* 1.28 (1.14-1.43) <0.0001*
C. 1.25 (1.15-1.36) <0.0001* 1.27 (1.12-1.43) <0.0001*
A: Model including analysis of cross-sectional IL-6 measurements at the corre
ately preceding timepoint after day 1).
B: Included model A and further corrected for the previously published risk pre
pitalization, the presence of oedema, systolic blood pressure, serum creatinine, sod
C: Included model B and further corrected for day 1 BNP for the analysis of d
ments for each corresponding timepoint (i.e. deltaBNP 1-2, 2-7 and 7-14) and the
IL-6 interleukin-6; BNP brain-type natriuretic peptide; HR hazard ratio; 95% CResults
Patients without available baseline IL-6 measurements
(n=442) were younger and more often male. The median
age of the study participants was 73 years (interquartile
range [IQR]: 63, 79) and 541 (34%) were women. Median
LVEF was 30% (IQR: 22-40), 100 (13%) patients had an
LVEF50% and the median BNP concentration in the
entire group was 449 pg/mL (IQR: 255, 801). The median
baseline IL-6 concentration was 11.1 pg/mL (IQR: 6.6,
20.9). Between baseline and day 7, concentrations of IL-6
decreased on average to a median of 10.1 pg/mL (IQR: 5.6-
18.5). Median log2-fold change between the two timepoints
was -0.13 (IQR: -0.86, 0.66). Patients with higher baseline
IL-6 levels were older [1st vs. 2nd vs. 3rd tertile median age
(IQR): 71 (61, 78) vs. 72 (64, 79) vs. 75 (66-80) years,
p<0.001], had lower estimated glomerular filtration rates
[49 (38, 65) vs. 45 (33, 59) vs. 43 (32, 55) mL/min/1.73 m2,
p<0.001], and higher BNP levels [326 (206, 594) vs. 475
(276, 840) vs. 551 (300, 957) pg/mL, p<0.001]. Sex and
LVEF50% were not associated with differences in IL-6
concentrations (p= 0.88 and 0.93 respectively).
At all examined time-points, higher cross-sectional con-
centrations of IL-6 were associated with a higher risk of
180-day all-cause mortality, independent of the previously
published risk model. Further correction for changes in
BNP did not attenuate the association between IL-6 and
higher 180-day all-cause mortality (Table 1). Serial IL-6
measurements also demonstrated incrementally stronger
associations with adverse outcomes proportional to the time
of the measurement since admission (Table 1). In a separate
analysis, each doubling of IL-6 concentrations between
baseline and day 7 conferred a significantly higher risk of
all-cause mortality when corrected for baseline IL-6 con-
centrations [hazard ratio (95% confidence interval): 1.26
(1.15-1.39), p<0.0001] and remained significant when cor-
rected for the existing risk model [1.24 (1.12-1.37),
p<0.0001], as well as for baseline BNP and changes in
BNP [1.18 (1.07-1.30), p=0.0013] (Figure 1). In total, 214/
1256 patients (17%) included in this analysis experienced atmary endpoint of all-cause mortality at 180 days. For each of the
s for the combined outcome and corrected for confounding factors
log2-fold change (doubling) of IL-6 levels. *p0.05.
Day 7 Day 14
HR (95% CI) p-value HR (95% CI) p-value
1.44 (1.30-1.60) <0.0001* 1.65 (1.46-1.85) <0.0001*
1.38 (1.23-1.55) <0.0001* 1.54 (1.36-1.74) <0.0001*
1.29 (1.14-1.45) <0.0001* 1.56 (1.37-1.77) <0.0001*
sponding designated timepoint (corrected for IL-6 measured at the immedi-
diction model for this cohort5. This included age, previous heart failure hos-
ium, blood urea nitrogen and albumin.
ay 1 IL-6 and for log2-fold change in BNP, between consecutive measure-
BNP measurements of the immediately preceding measurement timepoint.
I 95% confidence interval
Figure 1. Natural penalized splines with 95% confidence intervals of the hazard ratios for all-cause mortality at 180 days as a function of
Log2-Fold changes in IL-6 plasma concentrations between baseline (day 1) and day 7 after admission. The left-sided figure is only corrected
for IL-6 at day 1. The right-sided figure is corrected for the same but also includes the previously published predictive model for this cohort5,
BNP at day 1 and change in BNP between days 1 and 7. IL-6 interleukin-6; BNP brain natriuretic peptide.
810 Journal of Cardiac Failure Vol. 27 No. 7 July 2021least a doubling of their IL-6 concentrations between base-
line and day 7.Discussion
To our knowledge, this is the first study to demonstrate
that the temporal evolution patterns of IL-6 plasma concen-
trations are associated with prognosis in patients with AHF,
independent of known confounders or changes in BNP lev-
els. This complements previous studies that demonstrated
associations of serial IL-6 measurements with prognosis.
The largest of these studies evaluated 73 patients with AHF
and reported IL-6 plasma levels at 12, 24, 48 and 72 hours
and 1, 2 and 4 weeks after admission3. The authors con-
cluded that changes in IL-6 correlated with changes in pul-
monary capillary wedge pressure and that IL-6 was
significantly higher in patients with AHF that required
mechanical ventilation compared with those that did not.
Furthermore, IL-6 levels together with pulmonary pressures
decreased with time in stark contrast to interleukin-1b and
tumor necrosis factor-a which remained elevated through-
out the study. These findings suggest that IL-6 may better
reflect short-term clinical improvement.
Another study also evaluated the relationship between 11
healthy controls and 19 patients with AHF with regard to their
circulating monocyte subsets (classic, intermediate, non-clas-
sic) next to plasma IL-6 measurements at admission and dis-
charge, and reported that IL-6 levels and monocyte profiles
resemble those of healthy controls more closely following
standard-of-care treatment.7 IL-6 is the primary cytokine that
mediates the transition from acute to chronic inflammation bypromoting a shift from a neutrophilic to a mononuclear cell
infiltrate.8 Mononuclear cells are the main immune cells
responsible for producing IL-68 and the principal mediators of
the so-called cardiosplenic axis, a process in which heart-
spleen cross-talk mediates cardiotoxic immune responses.9
The cardiosplenic axis has in turn been shown to have an
important causative role in HF in numerous animal studies.
Namely, it has been demonstrated that splenectomy in mice
with ischaemic HF leads to reverse LV remodeling, reduced
LV size, improved LVEF and a reduced number of macro-
phages in the heart, while adoptive transfer of mononuclear
splenocytes from mice with HF to healthy mice produces a
HF phenotype with LV dilatation, reduced LVEF, interstitial
cardiac fibrosis and increased lung weights.9 Similarly, in
humans after an acute coronary syndrome, spleen metabolic
activity measured with positron emission tomography was
increased and was associated with pro-inflammatory changes
in leukocytes, elevated C-reactive protein and increased arte-
rial wall inflammation.10 A study of cardiac, splenic and bone
marrow autopsy findings in patients that died at different time-
points after having an acute myocardial infarction demon-
strated a clear monocyte depletion chiefly from the spleen and
secondarily from the bone marrow, which coincided with
monocytic infiltration of the heart.11 Lastly, there is also evi-
dence that splenic metabolic activity inversely correlates with
diastolic function in both mice and humans with HF with pre-
served ejection fraction, thus also suggesting that the actions
of the cardiosplenic axis are not limited to HF with reduced
ejection fraction. Collectively, our findings of the prognostic
capacity of serial IL-6 plasma concentrations in patients with
AHF may potentially indicate that those with persistently
Serial IL-6 in acute heart failure  Markousis-Mavrogenis et al 811elevated levels at each time-point or those with increases
between two time-points show persistent inflammation and
activation of the cardiosplenic axis. This is in line with the
finding that cross-sectional IL-6 levels exerted a stronger
effect on prognosis proportional to the time from study inclu-
sion. (strongest effect at 14 days), which also is in agreement
with the role of IL-6 in mediating the transition from acute to
chronic inflammation. IL-6 may thus serve as a potential thera-
peutic target in these patients.
Interestingly, changes in BNP did not influence the pre-
dictive capacity of serial IL-6 in our study, and the associa-
tion of IL-6 with prognosis increased in strength with
follow-up time. Myocardial stretch is known to induce both
the production of BNP and IL-612 , and BNP closely reflects
hemodynamic demands on the heart and decongestion.
However, the resolution of mechanical stress might not be
sufficient to halt IL-6 production, as might be the case with
the persistent activation of the cardiosplenic axis as stated
previously.11 Collectively, our findings suggest that IL-6 is
an important prognostic marker in HF, and support further
investigation into potential therapeutic applications involv-
ing the modulation IL-6 activity for the treatment of HF.
Conclusions
To conclude, this study demonstrates that the temporal
evolution patterns of IL-6 have additive prognostic value
independent of changes in BNP in patients with AHF, and
provides a rationale for further investigation of the magni-
tude and trajectories of these patterns as adjuncts to poten-
tial clinical applications in AHF.
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